Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab plus /- chemotherapy in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Ricciuti, Biagio
Champagne, Christine
Jones, Greg
Lazarus, Tadd Scott
Adeni, Anika E.
Cheng, Michael L.
Oxnard, Geoffrey R.
Awad, Mark M.
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Inivata, Cambridge, England
[4] Inivata Inc, Austin, TX USA
[5] Massachusetts Gen Hosp, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3518
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Comprehensive modeling of longitudinal circulating tumor DNA dynamics to predict clinical response to first-line immunotherapy and chemoimmunotherapy in advanced non-small cell lung cancer.
    Murray, Joseph Christopher
    Rhymee, Lamia
    Marrone, Kristen
    Naidoo, Jarushka
    Levy, Benjamin Philip
    Ferreira, Leonardo
    Rosner, Samuel
    Lanis, Mara
    Hann, Christine L.
    Feliciano, Josephine Louella
    Lam, Vincent K.
    Ettinger, David S.
    Illei, Peter Bela
    Wang, Chenguang
    Brahmer, Julie R.
    Forde, Patrick M.
    Velculescu, Victor E.
    Scharpf, Robert B.
    Anagnostou, Valsamo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Genomic landscape of non-small cell lung cancer (NSCLC) in India using circulating tumor DNA (ctDNA) in clinical practice
    Rauthan, A.
    Prabhash, K.
    Rohatgi, N.
    Thirumalairaj, R.
    Agarwal, A.
    Limaye, S.
    Batra, U.
    Raizada, N.
    Patil, P.
    Palanki, S. Dattatreya
    Sirohi, B.
    Dhar, A.
    Mukherjee, A. K.
    Joshi, N.
    Olsen, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1538
  • [23] Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Bernicker, Eric
    Li, Tianhong
    Wang, Victoria
    Ross, Jeffrey S.
    Young, Lauren
    Stephens, Philip J.
    Chung, Jon
    Shaw, Alice Tsang
    Ali, Siraj Mahamed
    Miller, Vincent A.
    Schrock, Alexa Betzig
    Spigel, David R.
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] COST-EFFECTIVENESS OF CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY AS THE FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER: A PRELIMINARY STUDY
    Xue, X.
    Ngorsuraches, S.
    Qian, J.
    VALUE IN HEALTH, 2024, 27 (06) : S353 - S353
  • [25] Associations between biomarkers and outcomes of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Gronberg, B. H.
    Lund-Iversen, M.
    Strom, E. H.
    Brustugun, O. T.
    Scott, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer
    Paladini, Luciano
    Pereira da Veiga, Cassia Rita
    Cerqueira, Erica
    Haas, Laura Chabrol
    Abadi, Marcia Datz
    Baldotto, Clarissa Serodio
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1185 - 1193
  • [27] Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
    Coco, Simona
    Alama, Angela
    Vanni, Irene
    Fontana, Vincenzo
    Genova, Carlo
    Dal Bello, Maria Giovanna
    Truini, Anna
    Rijavec, Erika
    Biello, Federica
    Sini, Claudio
    Burrafato, Giovanni
    Maggioni, Claudia
    Barletta, Giulia
    Grossi, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [28] Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy
    Shen, Jie
    Ye, Yuanqing
    Chang, David W.
    Huang, Maosheng
    Heymach, John V.
    Roth, Jack A.
    Wu, Xifeng
    Zhao, Hua
    LUNG CANCER, 2017, 114 : 70 - 78
  • [29] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
    Chouaid, C.
    Bensimon, L.
    Tardu, J.
    Millier, A.
    Insinga, R.
    Rai, A.
    Levy-Bachelot, L.
    Levy, P.
    VALUE IN HEALTH, 2020, 23 : S433 - S433
  • [30] EGFR Clonality and Tumor Mutation Burden (TMB) by Circulating Tumor DNA (ctDNA) Sequencing in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Ai, X.
    Lin, Y.
    Zhang, J.
    Xie, C.
    Liu, A.
    Hu, X.
    Zhao, Q.
    Zang, Y.
    Rao, C.
    Hu, X.
    Chang, L.
    Li, Q.
    Guan, Y.
    Chen, R.
    Yi, X.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S412 - S413
12345